List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

A feline exclusive veterinarian opposes the FDA's actions regarding compounded drugs, arguing that they are critical for providing immediate and appropriate care to patients. The commenter highlights specific medications where commercial alternatives are either unavailable, toxic, or provide incorrect dosages for small animals.

A veterinary professional (implied by the description of treating feline patients) is requesting the inclusion of a compounded oral buprenorphine suspension on the approved list. They argue that the compounded version is more palatable and effective than injectable alternatives for treating feline urinary obstructions, ultimately improving patient compliance and outcomes.

A veterinary professional who treats wildlife argues in favor of allowing compounded buprenorphine. They state that commercially available concentrations are insufficient for the diverse sizes and dose requirements of various wildlife species, making compounded options essential for effective pain management.

An emergency veterinarian is requesting the inclusion of several specific medications (Apomorphine, Gabapentin, Metronidazole, Hydromorphone, Buprenorphine, and Phenobarbital) on the list of bulk drug substances for compounding. The commenter argues that these medications are necessary for treating specific conditions, managing pain, and providing emergency care for animals when commercial alternatives are unavailable, unsafe, or ineffective.

An emergency veterinarian is requesting the inclusion of several specific medications (Apomorphine, Gabapentin, Metronidazole, Hydromorphone, Buprenorphine, and Phenobarbital) on the list of bulk drug substances for compounding. The commenter argues that these medications are essential for treating specific conditions, managing pain, and providing safe alternatives for animals that cannot tolerate commercially available products.

A veterinary clinic is requesting that compounded Buprenorphine ER be included on the list of bulk drug substances for office stock. They argue that the commercial version lacks an extended-release formulation and that having the compounded version on hand is ethically imperative for their pain management protocols.

A veterinary hospital is requesting that compounded Buprenorphine ER be included on the list of bulk drug substances for office stock. They argue that the commercial version lacks the necessary extended-release formulation required for their ethical obligation to provide long-acting pain management for patients.

A veterinary professional requests that Doxycycline, Metronidazole, and buprenorphine be added to the list of bulk drug substances for compounding office stock for companion animals. The commenter argues that standard manufactured sizes do not meet diverse weight requirements and that compounded multi-dose vials are necessary to overcome delivery delays and administration difficulties.